Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Friday . The company traded as high as $9.99 and last traded at $9.88, with a volume of 947008 shares trading hands. The stock had previously closed at $9.56.
Analyst Ratings Changes
A number of research analysts recently weighed in on the stock. Wall Street Zen cut shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, June 6th. Cantor Fitzgerald initiated coverage on shares of Trevi Therapeutics in a report on Tuesday, July 1st. They issued an "overweight" rating and a $25.00 target price for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Trevi Therapeutics in a report on Saturday, September 27th. Needham & Company LLC decreased their price target on shares of Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Finally, Raymond James Financial decreased their price target on shares of Trevi Therapeutics from $29.00 to $27.00 and set a "strong-buy" rating for the company in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $21.75.
Check Out Our Latest Analysis on Trevi Therapeutics
Trevi Therapeutics Stock Performance
The company has a market cap of $1.20 billion, a PE ratio of -23.52 and a beta of 0.74. The stock's 50-day simple moving average is $7.91 and its 200 day simple moving average is $6.86.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. On average, sell-side analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.
Institutional Investors Weigh In On Trevi Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of TRVI. Russell Investments Group Ltd. boosted its position in shares of Trevi Therapeutics by 194.5% in the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company's stock worth $25,000 after acquiring an additional 2,996 shares during the last quarter. Farther Finance Advisors LLC lifted its position in Trevi Therapeutics by 15,969.1% during the second quarter. Farther Finance Advisors LLC now owns 8,838 shares of the company's stock valued at $48,000 after buying an additional 8,783 shares in the last quarter. Strs Ohio acquired a new position in Trevi Therapeutics during the first quarter valued at approximately $52,000. Catalyst Funds Management Pty Ltd acquired a new position in Trevi Therapeutics during the second quarter valued at approximately $56,000. Finally, Squarepoint Ops LLC acquired a new position in Trevi Therapeutics during the fourth quarter valued at approximately $58,000. 95.76% of the stock is currently owned by hedge funds and other institutional investors.
About Trevi Therapeutics
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
